H. Harvey

First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.
20206 citationsauthor #11
Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer
20192 citationsauthor #3
A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.
20190 citationsauthor #11
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
201791 citationsauthor #8
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
2017174 citationsauthor #6
Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
20160 citationsauthor #9
Reverse-phase protein microarray (RPPA) analysis of PD-L1 and growth factor receptor signal transduction pathways in hormone receptor (HR)-positive primary breast cancer tissue and correlation with relapse.
20160 citationsauthor #9
Significance of CA 27.29 (MUC 1 glycoprotein) levels in patients with breast cancer.
20161 citationsauthor #2
Primary female breast sarcoma: clinicopathological features, treatment and prognosis
201653 citationsauthor #4
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
2016431 citationsauthor #6
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
20159 citationsauthor #9
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
201584 citationsauthor #7
Endoscopic ultrasound-guided ethanol ablation of a large metastatic carcinoid tumor: success with a note of caution
20145 citationsauthor #2
Molecular profiling of 6,892 colorectal cancer patients to identify potential treatment options.
20140 citationsauthor #6
Stem Cell Transplantation Therapy-induced Acute Lymphocytic Leukemia with the 11q23 Translocation: 2 Cases and a Review of the Literature
20140 citationsauthor #6
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
201419 citationsauthor #9
Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
201437 citationsauthor #6
Abstract 1176: Pharmacokinetic monitoring of 5-FU appears beneficial in stage II-IV colorectal cancer patients treated with different 5-FU-based chemotherapeutic regimens.
20130 citationsauthor #6
Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.
201320 citationsauthor #9
Update on clinical trials: genetic targets in breast cancer.
201310 citationsauthor #3
Abstract P2-16-05: Efficacy of ABT-888 (veliparib) in patients with BRCA-associated breast cancer
20132 citationsauthor #9
Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series
201126 citationsauthor #2
Clinical Utility of Monitoring Serial CA 27.29 in Patients with DifferentStage of Breast Cancer
20112 citationsauthor #4
Does a change from IHC to FISH enhance patient selection for HER2 therapy?
20110 citationsauthor #4
Compliance with calcium and vitamin D use in patients treated with zoledronic acid.
20110 citationsauthor #3
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting.
201124 citationsauthor #8
Phase I Trial of Zoledronic Acid + Imatinib Mesylate (Gleevec) in Patients With Bone Metastases
20109 citationsauthor #3
Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer
201067 citationsauthor #4
Incidence of peripheral neuropathy in high-risk early-stage breast cancer patients receiving dose-dense paclitaxel in central Pennsylvania.
20090 citationsauthor #3
Biology of bone metastases: causes and consequences.
200741 citationsauthor #1
Toremifene: an evaluation of its safety profile.
200659 citationsauthor #1
Elevated serum ras level predicts decreased survival in patients with hematologic malignancies.
20063 citationsauthor #6
Circulating tumor cells in adjuvant breast cancer patients
20058 citationsauthor #3
Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma
200517 citationsauthor #3
Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
2005106 citationsauthor #5
Phase II trial of gemcitabine and irinotecan plus celecoxib in advanced adenocarcinoma of the pancreas
20058 citationsauthor #5
Hormonal therapy for breast cancer.
20050 citationsauthor #1
Treatment of advanced pancreatic cancer with opioid growth factor: phase I
200461 citationsauthor #4
Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma
200414 citationsauthor #3
Effect of aromatase inhibitor therapy on cognitive function.
20041 citationsauthor #4
Pretreatment serum uPA and survival in patients with advanced pancreatic cancer.
20043 citationsauthor #9
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
20049 citationsauthor #1
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
200413 citationsauthor #2
Aromatase inhibitor development for treatment of breast cancer
200427 citationsauthor #3
Recurrent nodular metastatic melanoma to the placenta in a 33-year-old twin-gravida woman: a case presentation, literature review, and discussion of current therapeutic options
20040 citationsauthor #4
Therapeutic Use of Bisphosphonates in Breast Cancer
20031 citationsauthor #1
Development of Improved Aromatase Inhibitors
20030 citationsauthor #2
Historical Development of Aromatase Inhibitors
20030 citationsauthor #2
Biology of Aromatase
20030 citationsauthor #2
Future Perspectives in the Clinical Development of Aromatase Inhibitors
20030 citationsauthor #2
Medical Management of Bone Metastases
20030 citationsauthor #2
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
2003143 citationsauthor #5
Selection of Patients for Aromatase Inhibition Therapy
20030 citationsauthor #2
Metastatic breast cancer: overview of treatment.
200353 citationsauthor #2
Aromatase inhibitors in breast cancer
20025 citationsauthor #6
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
2002298 citationsauthor #7
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
200292 citationsauthor #6
Commentary (Harvey): Nonsteroidal and Steroidal Aromatase Inhibitors in Breast Cancer
20010 citationsauthor #1
Safety a nd E fficacy o f B isphosphonates B eyond 2 4 M onths in C ancer P atients
20010 citationsauthor #2
Treatment of advanced pancreatic cancer patients with opioid growth factor
20002 citationsauthor #4
Aromatase Inhibitors in Breast Carcinoma
19992 citationsauthor #1
Use of aromatase inhibitors in breast carcinoma.
1999180 citationsauthor #2
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
199926 citationsauthor #6
Combined chemoradiotherapy for unresectable pancreatic cancer.
199917 citationsauthor #2
Emerging role of aromatase inhibitors in the treatment of breast cancer.
199834 citationsauthor #1
INITIAL CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENT QUALITY OF LIFE
199827 citationsauthor #1
Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma
199719 citationsauthor #1
Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma.
199725 citationsauthor #1
Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2.
199713 citationsauthor #2
Phase I study combining tumor necrosis factor with interferon-α and interleukin-2
199728 citationsauthor #2
Prospective evaluation of expandable esophageal stents (EES) on dysphagia, quality of life (QLI), and karnofsky scores (KP)
19970 citationsauthor #4
Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells.
1996159 citationsauthor #4
The role of bisphosphonates in the treatment of bone metastases — the U.S. experience
199611 citationsauthor #1
Aromatase inhibitors in clinical practice: current status and a look to the future.
199625 citationsauthor #1
946 CGP 42446-phase I study of a new bisphosphonate in patients with osteolytic bone metastases
19950 citationsauthor #3
Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.
1995185 citationsauthor #4
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
1995325 citationsauthor #7
Ovarian cancer: screening, treatment, and followup.
1995572 citationsauthor #6
The management of hypercalcemia of malignancy
199513 citationsauthor #1
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer
1995114 citationsauthor #3
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.
199319 citationsauthor #3
Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.
199330 citationsauthor #2
Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.
1992142 citationsauthor #8
Hormonal and immunological regulation of 2', 5'-oligoadenylate synthetase activity in human peripheral blood mononuclear cells.
19923 citationsauthor #5
Prognostic value of breast cancer aromatase
199282 citationsauthor #4
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
199144 citationsauthor #4
Elevated plasma platelet-derived growth factor B-chain levels in cancer patients.
199149 citationsauthor #9
Advanced head and neck cancer: low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin.
19903 citationsauthor #2
Endocrine treatment of breast cancer in women.
1990414 citationsauthor #3
Somatostatin analogues in the treatment of breast and prostate cancer.
199017 citationsauthor #4
Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.
199074 citationsauthor #3
FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.
19902 citationsauthor #2
A phase I trial of CGS 16949a. A new aromatase inhibitor
199068 citationsauthor #2
Novel Approaches to the Treatment of Advanced Prostate Cancer
19900 citationsauthor #5
The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
199062 citationsauthor #5
Predictors of Grief Among Spouses of Deceased Cancer Patients
198931 citationsauthor #3
Immunologic monitoring studies in advanced cancer patients treated with recombinant human gamma interferon (IFN-gamma 4A).
19891 citationsauthor #3
Inhibition of aromatase with CGS 16949A in postmenopausal women.
198996 citationsauthor #4
A phase I study of hepatic arterial infusion using difluoromethylornithine
19895 citationsauthor #2
Chemotherapy Plus RA233 in the Treatment of Oat Cell Lung Cancer
19895 citationsauthor #2

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT